➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Harvard Business School
Boehringer Ingelheim
Dow
Merck

Last Updated: July 7, 2020

DrugPatentWatch Database Preview

DROPERIDOL Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

US ANDA Litigation and Generic Entry Outlook for Droperidol

A generic version of DROPERIDOL was approved as droperidol by HOSPIRA on February 29th, 1988.

  Start Trial

Drug patent expirations by year for DROPERIDOL
Recent Clinical Trials for DROPERIDOL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Assiut UniversityN/A
Medical University of GdanskN/A
Central Hospital, Nancy, FrancePhase 3

See all DROPERIDOL clinical trials

Pharmacology for DROPERIDOL
Medical Subject Heading (MeSH) Categories for DROPERIDOL

US Patents and Regulatory Information for DROPERIDOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abraxis Pharm DROPERIDOL droperidol INJECTABLE;INJECTION 070992-001 Nov 17, 1986 DISCN No No   Start Trial   Start Trial   Start Trial
Watson Labs DROPERIDOL droperidol INJECTABLE;INJECTION 073523-001 Nov 27, 1991 DISCN No No   Start Trial   Start Trial   Start Trial
Hospira DROPERIDOL droperidol INJECTABLE;INJECTION 071981-001 Feb 29, 1988 AP RX No No   Start Trial   Start Trial   Start Trial
Astrazeneca DROPERIDOL droperidol INJECTABLE;INJECTION 072018-001 Oct 20, 1988 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Harvard Business School
Boehringer Ingelheim
Dow
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.